-

$undefined

N/A

(N/A)

Artiva Biotherapeutics :ARTV Artiva Biotherapeutics is an immunotherapy company with the ability to produce off-the-shelf, allogeneic NK cell therapies at a massive scale. Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our lead program, AlloNK®, is an allogeneic, non-genetically modified NK cell therapy candidate designed to enhance the activity of monoclonal antibodies or NK cell engagers. AlloNK is currently in clinical trials in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis and for treatment of Non-Hodgkin Lymphoma, as well as in combination with Affimed’s innate cell engager AFM13 for the treatment of patients with relapsed/refractory CD30-positive lymphomas.

Location: San Diego, California, United States | Website: https://www.artivabio.com | Industry: | Sector:

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-101.4M

Cash

185.4M

Avg Qtr Burn

-13.76M

Short % of Float

19.43%

Insider Ownership

22.63%

Institutional Own.

90.84%

Qtr Updated

12/31/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
AlloNK® (AB-101) + rituximab Details Cancer, r/r B-cell non-Hodgkin’s lymphoma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AlloNK® (AB-101) + rituximab Details Rheumatoid arthritis, Pemphigus vulgaris, Granulomatosis with polyangiitis/microscopic polyangiitis, Systemic lupus erythematosus	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AlloNK® (AB-101) + rituximab or obinutuzumab Details Systemic lupus erythematosus, Lupus nephritis	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.